康寧傑瑞製藥-B(09966.HK)上半年研發開支大幅增至1.34億元
格隆匯8月28日丨康寧傑瑞製藥-B(09966.HK)公佈,截至2020年6月30日止6個月,集團錄得其他收入為4430萬元人民幣(單位下同),截至2019年6月30日止6個月為1100萬元;錄得虧損及全面開支總額為1.03億元,截至2019年6月30日止6個月為5880萬元。
截至2020年6月30日止6個月,研發開支較截至2019年6月30日止6個月的5580萬元增加7790萬元至1.34億元,主要原因為(i)正在進行的臨牀試驗數量增加;(ii)臨牀研究規模擴大;(iii)推進候選藥物臨牀試驗;(iv)因研發員工增加及因向員工授出期權導致薪酬增加,從而導致員工成本增加;及(v)臨牀試驗增加導致用藥需求增加,進而導致生產成本增加。
迄今為止,集團計劃於2020年開始在中國建立集團自身的商業化團隊,將重心初步放在後期候選藥物及建立一支致力於醫療事宜及政府事宜的團隊,為將來於2022年推出KN046作準備。
此外,集團計劃繼續擴大集團的團隊以積極尋求來自第三方付款方及政府報銷項目的保險及報銷機會,從而支持KN046的持續商業運作及即將推出的KN026。集團期望將集團的團隊覆蓋到中國的主要省市,尤其是經濟相對發達及可支配收入水平相對較高的省市。集團打算繼續擴大集團的團隊以期推出更多的產品及獲批更多的適應症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.